West Pharmaceutical Services Inc (WST) Stock Price & Analysis
West Pharmaceutical Services Inc (WST) rose 4.66% to USD 334.66 as of June 9, 2026 at 22:37 UTC, according to Nexqual real-time market data.
WST last closed at USD 319.75; the session ranged USD 326.73–336.82 on volume of 753,767 shares. Market capitalization is $23.64B, with a 52-week range of USD 206.8–336.82 (NYQ). Source: Nexqual, June 9, 2026 at 22:37 UTC.
Key Statistics (as of June 9, 2026 at 22:37 UTC)
| Price | USD 334.66 |
|---|---|
| Change | ▲ 4.66% (up) |
| Previous Close | USD 319.75 |
| Open | USD 327.45 |
| Day Range | USD 326.73 – 336.82 |
| 52-Week Range | USD 206.8 – 336.82 |
| Volume | 753,767 shares |
| Market Cap | $23.64B |
| Exchange | NYQ |
Technical Analysis (WST)
Nexqual's technical model rates WST "BUY" based on 5 bullish and 3 bearish signals across 124 daily candles, as of June 9, 2026 at 22:37 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 70.09 (overbought) |
| vs SMA50 | Above (USD 294.62) |
| MACD | 7.52 (positive) |
Analyst Ratings (WST)
Wall Street analysts rate WST "Strong Buy" based on 14 analysts, with a mean price target of USD 352.36 (range USD 310–400), per Nexqual as of June 9, 2026 at 22:37 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 352.36 |
| High Target | USD 400 |
| Low Target | USD 310 |
| Buy / Hold / Sell | 13 / 2 / 0 |
Earnings (WST)
| Next Earnings Date | 2026-07-23 |
|---|---|
| EPS Estimate | USD 2.08 |
| Revenue Estimate | $838.32M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 2.13 vs est 1.68 ▲ beat |
| 2025-12-31 | USD 2.04 vs est 1.83 ▲ beat |
| 2025-09-30 | USD 1.96 vs est 1.71 ▲ beat |
| 2025-06-30 | USD 1.84 vs est 1.54 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:37 UTC.
Financials & Fundamentals (WST)
| Total Revenue | $3.22B |
|---|---|
| Revenue Growth (YoY) | +21.00% |
| Gross Margin | +36.28% |
| Operating Margin | +21.70% |
| Profit Margin | +16.85% |
| ROE | +19.13% |
| Debt / Equity | 10.73 |
| Current Ratio | 2.71 |
| Total Cash | $521.40M |
| Total Debt | $321.00M |
| Free Cash Flow | $275.66M |
Source: Nexqual, June 9, 2026 at 22:37 UTC.
Financial Health Score (WST)
Nexqual rates West Pharmaceutical Services Inc's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 22:37 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 36%, operating 22% |
| Balance Sheet | Strong — $521M cash vs $321M debt, net cash position |
| Cash Flow | Solid — FCF $276M, 9% margin |
| Efficiency | Solid — ROE 19%, ROA 11.2% |
Ownership (WST)
| Insider Ownership | +0.64% |
|---|---|
| Institutional Ownership | +103.95% |
| Shares Outstanding | 70.65M |
| Float | 70.16M |
| Short % of Float | +3.77% |
Source: Nexqual, June 9, 2026 at 22:37 UTC.
Leadership (WST)
West Pharmaceutical Services Inc is led by Eric M. Green (age 55), Non-Independent Chair of the Board, President & CEO, per Nexqual as of June 9, 2026 at 22:37 UTC.
| Non-Independent Chair of the Board, President & CEO | Eric M. Green (age 55) |
|---|---|
| Senior VP & CFO | Robert W. McMahon C.M.A. (age 56) |
| Senior VP & CTO | Devesh Mathur |
| Vice President of Investor Relations | John P. Sweeney C.F.A. |
| Vice President of Global Communications | Michele Polinsky |
Major Backers & Investors (WST)
Notable institutional backers of West Pharmaceutical Services Inc include T. Rowe Price, Artisan Partners Limited Partnership, Generation Investment Management LLP, according to Nexqual as of June 9, 2026 at 22:37 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 4.81% |
| Artisan Partners Limited Partnership | 3.76% |
| Generation Investment Management LLP | 3.18% |
| Morgan Stanley | 2.06% |
| Fidelity | 1.3% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 21.84% |
| BlackRock | 11% |
| State Street | 5.88% |
| BNY Mellon | 3.49% |
| Geode Capital | 2.71% |
Source: Nexqual, June 9, 2026 at 22:37 UTC.
From West Pharmaceutical Services Inc's Latest SEC 10-K Filing (filed 2026-02-17)
Key Strengths & Strategy (as disclosed to the SEC)
- In addition to our Proprietary Products product portfolio, we provide our customers with a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support.
- Our products include a variety of primary proprietary packaging, containment solutions, reconstitution and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services and integrated solutions.
- Proprietary Products Segment Our Proprietary Products reportable segment offers elastomers & primary containment, drug delivery devices, integrated systems, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers.
- This focus on quality includes a commitment to excellence in manufacturing, scientific and technical expertise and management, which enables us to partner with our customers in order to deliver safe, effective drug products to patients quickly and efficiently.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| STE | STERIS plc (Ireland) | USD 212.88 | ▲ 0.25% |
| TFX | Teleflex Incorporated | USD 135.75 | ▲ 4.55% |
| MTD | Mettler-Toledo International, I | USD 1,162.79 | ▲ 0.73% |
| ROP | Roper Technologies, Inc. | USD 335.37 | ▲ 0.96% |
| COO | The Cooper Companies, Inc. | USD 68.62 | ▲ 1.9% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:37 UTC. This page is informational and not investment advice.